News

Brain damage caused by HIV can begin soon after infection, according to new research, but initiating antiretroviral therapy drugs can halt the damage.

In case you missed them, we've compiled the top 5 articles from this past week.

A new study shows the benefits of widespread antibiotic distribution, but what about concerns about encouraging antibiotic resistance?

An ambitious new trial aims to confirm that people living with HIV can be kidney donors to HIV recipients, shortening the time those recipients wait for a transplant.

Rates of a lesser known virus related to HIV called HTLV-1 have surged in some of Australia’s Aboriginal communities, and now the country’s health officials are facing a global outcry to act.

A study shows that pharmacist-driven education and encouragement of antibiotic self-stewardship can decrease the duration of therapy for broad-spectrum antibiotics.

A recent review article looks at literature exploring risk factors and C. diff epidemiology to inform future preventive strategies.

The FDA has launched an investigation into a multistate outbreak of Burkholderia cepacia that has been linked with cleansing foam used in hospitals and home-health care settings.

An FDA inspection at Rose Acre Farms’ Hyde County Farm found rodents, insects, and poor sanitation shortly before the announcement of the multistate Salmonella outbreak.

An economic evaluation finds that a bundled approach of stronger hand hygiene and improved environmental cleaning proved to be the best combination for reducing C. diff.

A new literature review offers a summary of the latest research into uncomplicated bacteremia.

A phase 2 trial of an experimental universal flu vaccine is moving forward with sponsorship from The National Institute of Allergy and Infectious Diseases.

A recent study finds that ibrutinib may be associated with serious infections in patients with lymphoid cancer.

The burden of prostate, breast, and lung cancers among those living with HIV is expected to rise by 2030.

Novavax announces that enrollment in phase 3 Prepare trial has reached approximately 4,600 participants, of whom, at least 3,000 have received the RSV F vaccine.

Combatting CRE requires analysis trends within patients - a new study is filling the void.

If clinical development progresses, the PaxVax vaccine could potentially become the first vaccine approved by the FDA for the prevention of chikungunya.

A recent study finds high dose of oral vancomycin may be optimal treatment for C. difficile.

In case you missed them, we’ve compiled a list of the latest recalls posted this week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The World Health Organization has a new way to identify cost-effective measures to address the increasing prevalence of drug-resistant HIV in sub-Saharan Africa.

A recent study has found that a single-dose of Merck's Ebola vaccine delivers antibodies that can last for 1 to 2 years.

Data from the IGNITE4 phase 3 trial supports the use of eravacycline for the treatment of complicated intra-abdominal infections (cIAI), including infections caused by pathogens resistant to other antibiotics.

New software unveiled last month suggests hospitals could make patient-specific predictions of antibiotic susceptibility.

Tuberculosis treatment is long and rigorous, but a new study by Johns Hopkins School of Medicine suggests that a smartphone application may help patients adhere to their daily medication regimens.

The first fatality associated with the ongoing multistate E. coli outbreak linked with romaine lettuce has been reported by the CDC.

The FDA has granted QIDP and Fast Track Designations for the oral formulation of SCY-078 for the treatment of vulvovaginal candidiasis.

However, the FDA's Drug Advisory Committee did not feel that there was substantial evidence regarding the safety and effectiveness of plazomicin for the treatment of bloodstream infections in patients with limited or no treatment options.